Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
Article first published online: 5 FEB 2014
© 2014 The Authors. Journal of Veterinary Pharmacology and Therapeutics Published by John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Journal of Veterinary Pharmacology and Therapeutics
Volume 37, Issue 4, pages 317–324, August 2014
How to Cite
Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J. vet. Pharmacol. Therap. 37, 317–324., , , , , .
- Issue published online: 3 JUL 2014
- Article first published online: 5 FEB 2014
- Manuscript Accepted: 18 NOV 2013
- Manuscript Received: 18 JUL 2013
|jvp12101-sup-0001-FigS1.docx||Word document||40K||Figure S1. Sequence homology between human and canine JAK family members.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.